Barclays initiates Viatris (VTRS) with overweight as pharma sentiment improves

Viatris Inc. (NASDAQ:VTRS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 9, Barclays ...
Nasdaq

Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan

Viatris VTRS announced the acquisition of Tokyo-based Aculys Pharma, a clinical-stage biopharmaceutical company specializing in neurological therapies. The deal grants Viatris the rights to develop ...
Morningstar

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

PITTSBURGH, Oct. 15, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has acquired Aculys Pharma, Inc., a clinical stage biopharmaceutical company ...
Seeking Alpha

Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis ...

PITTSBURGH, and FARMINGTON HILLS, Mich., Sept. 27, 2023 /PRNewswire/ -- Viatris Inc. (VTRS), a global healthcare company, and Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic ...
Seeking Alpha

Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis

PITTSBURGH and NESS ZIONA, Israel, Aug. 7, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development ...